For once, France has made a risky bet.
That of betting on a still experimental treatment against Covid-19: bamlanivimab, a monoclonal antibody produced by the American laboratory Eli Lilly.
A temporary authorization for use was issued Wednesday in France.
Olivier Véran confirmed the purchase of
"a few tens of thousands of doses
" without going into details.
What exactly do we know about this treatment, its effectiveness and its conditions of use in France?
Read also:
France prepares to use monoclonal antibodies
What are monoclonal antibodies?
These are antibodies identical to those produced naturally by our body, but here manufactured in bioreactors.
They are said to be “monoclonal” because they are all identical for a given disease.
They are obtained by cloning the genetic sequence of the B lymphocyte which produced it in the human body.
This piece of DNA is then integrated into the genome of factory cells, which will synthesize antibodies in very large quantities.
How it works?
This article is for subscribers only.
You have 68% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in